FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2052090282> ?p ?o ?g. }

• W2052090282 endingPage "1025" @default.
• W2052090282 startingPage "1019" @default.
• W2052090282 abstract "The aim of this phase I/II study was to determine the maximum tolerated dose (MTD) and the dose-limiting toxicities of chronic oral etoposide given on days 1-10 followed by rescue with subcutaneous (s.c.) granulocyte-macrophage colony-stimulating factor (GM-CSF) on days 12-19 as second-line chemotherapy in platinum-pretreated patients (pts) with advanced ovarian carcinoma. Cohorts of three to six pts were treated with doses of oral etoposide from 750 mg m(-2) cycle(-1) escalated to 1250 mg m(-2) cycle(-1) over 10 days, every 3 weeks. Subcutaneous GM-CSF, 400 mug once daily, days 12-19, was added if dose-limiting granulocytopenia was encountered. In total, 18 pts with a median Karnofsky index of 80% (range, 70-100%) and a median time elapsed since the last platinum dose of 10 months (range, 1-24 months), 30% of whom showed visceral metastases, were treated at four dose levels (DLs) of oral etoposide on days 1-10 of each cycle as follows: DL 1, 750 mg m(-2) cycle(-1), without GM-CSF, three pts; DL 2, 1000 mg m(-2) cycle(-1), without GM-CSF, three pts; DL 3, 1000 mg m(-2) cycle(-1), with GM-CSF, six pts; and DL 4, 1250 mg m(-2) cycle(-1), with GM-CSF, six pts. All pts were assessable for toxicity and 16 pts for response. Dose-limiting toxicity (DLT) was reached at DL 4 by three of six pts, showing World Health Organization (WHO) toxicity grade 4. One patient died from gram-negative sepsis associated with granulocytopenia grade 4. Two more pts developed uncomplicated granulocytopenia grade 4. Thus, we recommend that DL 3 can be used for further phase II evaluation (i.e. oral etoposide 1000 mg m(-2) cycle(-1), days 1-10, followed by s.c. GM-CSF 400 mug, days 12-19). The clinical complete or partial responses in each patient cohort were: DL 1, one of three pts; DL 2, one of three pts; DL 3, three of five pts; and DL 4, two of five pts. In conclusion, in this phase I/II study, we defined the MTD and the dose recommended for the therapy with oral etoposide given over 10 days followed by s.c. GM-CSF in platinum-pretreated patients with advanced ovarian cancer. Our data demonstrate encouraging activity of this regimen and strongly support its further investigation in a phase II study." @default.
• W2052090282 created "2016-06-24" @default.
• W2052090282 creator A5014683644 @default.
• W2052090282 creator A5018699045 @default.
• W2052090282 creator A5019584888 @default.
• W2052090282 creator A5042756447 @default.
• W2052090282 creator A5055137516 @default.
• W2052090282 creator A5066828315 @default.
• W2052090282 creator A5068183698 @default.
• W2052090282 date "2005-03-01" @default.
• W2052090282 modified "2023-10-18" @default.
• W2052090282 title "Phase I/II study of oral etoposide plus GM-CSF as second-line chemotherapy in platinum-pretreated patients with advanced ovarian cancer" @default.
• W2052090282 cites W1543697093 @default.
• W2052090282 cites W176786848 @default.
• W2052090282 cites W1825053022 @default.
• W2052090282 cites W1828446274 @default.
• W2052090282 cites W1902459117 @default.
• W2052090282 cites W1939163116 @default.
• W2052090282 cites W1955033393 @default.
• W2052090282 cites W1955998452 @default.
• W2052090282 cites W1960327677 @default.
• W2052090282 cites W1965257515 @default.
• W2052090282 cites W1971445820 @default.
• W2052090282 cites W1972732503 @default.
• W2052090282 cites W1988317704 @default.
• W2052090282 cites W2010282089 @default.
• W2052090282 cites W2010906875 @default.
• W2052090282 cites W2048635266 @default.
• W2052090282 cites W2049014582 @default.
• W2052090282 cites W2051934725 @default.
• W2052090282 cites W2055317360 @default.
• W2052090282 cites W2079294431 @default.
• W2052090282 cites W2089308365 @default.
• W2052090282 cites W2255570302 @default.
• W2052090282 cites W2276477497 @default.
• W2052090282 cites W2319708900 @default.
• W2052090282 cites W2343271354 @default.
• W2052090282 cites W2408992192 @default.
• W2052090282 cites W2410869247 @default.
• W2052090282 cites W2415724037 @default.
• W2052090282 cites W33925816 @default.
• W2052090282 cites W41316188 @default.
• W2052090282 cites W4285719527 @default.
• W2052090282 cites W579496000 @default.
• W2052090282 cites W58457943 @default.
• W2052090282 doi "https://doi.org/10.1038/sj.bjc.6602427" @default.
• W2052090282 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2361931" @default.
• W2052090282 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15756278" @default.
• W2052090282 hasPublicationYear "2005" @default.
• W2052090282 type Work @default.
• W2052090282 sameAs 2052090282 @default.
• W2052090282 citedByCount "10" @default.
• W2052090282 countsByYear W20520902822012 @default.
• W2052090282 countsByYear W20520902822017 @default.
• W2052090282 countsByYear W20520902822018 @default.
• W2052090282 countsByYear W20520902822020 @default.
• W2052090282 countsByYear W20520902822022 @default.
• W2052090282 crossrefType "journal-article" @default.
• W2052090282 hasAuthorship W2052090282A5014683644 @default.
• W2052090282 hasAuthorship W2052090282A5018699045 @default.
• W2052090282 hasAuthorship W2052090282A5019584888 @default.
• W2052090282 hasAuthorship W2052090282A5042756447 @default.
• W2052090282 hasAuthorship W2052090282A5055137516 @default.
• W2052090282 hasAuthorship W2052090282A5066828315 @default.
• W2052090282 hasAuthorship W2052090282A5068183698 @default.
• W2052090282 hasBestOaLocation W20520902821 @default.
• W2052090282 hasConcept C121608353 @default.
• W2052090282 hasConcept C126322002 @default.
• W2052090282 hasConcept C126894567 @default.
• W2052090282 hasConcept C141071460 @default.
• W2052090282 hasConcept C2776694085 @default.
• W2052090282 hasConcept C2778119113 @default.
• W2052090282 hasConcept C2780427987 @default.
• W2052090282 hasConcept C29730261 @default.
• W2052090282 hasConcept C71924100 @default.
• W2052090282 hasConcept C90924648 @default.
• W2052090282 hasConceptScore W2052090282C121608353 @default.
• W2052090282 hasConceptScore W2052090282C126322002 @default.
• W2052090282 hasConceptScore W2052090282C126894567 @default.
• W2052090282 hasConceptScore W2052090282C141071460 @default.
• W2052090282 hasConceptScore W2052090282C2776694085 @default.
• W2052090282 hasConceptScore W2052090282C2778119113 @default.
• W2052090282 hasConceptScore W2052090282C2780427987 @default.
• W2052090282 hasConceptScore W2052090282C29730261 @default.
• W2052090282 hasConceptScore W2052090282C71924100 @default.
• W2052090282 hasConceptScore W2052090282C90924648 @default.
• W2052090282 hasIssue "6" @default.
• W2052090282 hasLocation W20520902821 @default.
• W2052090282 hasLocation W20520902822 @default.
• W2052090282 hasLocation W20520902823 @default.
• W2052090282 hasLocation W20520902824 @default.
• W2052090282 hasOpenAccess W2052090282 @default.
• W2052090282 hasPrimaryLocation W20520902821 @default.
• W2052090282 hasRelatedWork W2003938723 @default.
• W2052090282 hasRelatedWork W2006516489 @default.
• W2052090282 hasRelatedWork W2047967234 @default.
• W2052090282 hasRelatedWork W2118496982 @default.
• W2052090282 hasRelatedWork W2218774205 @default.

• next